Ireland Axial Spondyloarthritis (axSpA) Market (2025-2031) | Trends, Share, Industry, Competitive Landscape, Outlook, Growth, Forecast, Value, Size & Revenue, Companies, Segmentation, Analysis

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Ireland Country Macro Economic Indicators

3.2 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, 2021 & 2031F

3.3 Ireland Axial Spondyloarthritis (axSpA) Market - Industry Life Cycle

3.4 Ireland Axial Spondyloarthritis (axSpA) Market - Porter's Five Forces

3.5 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume Share, By Types, 2021 & 2031F

3.6 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness and diagnosis of axial spondyloarthritis (AxSpA) in Ireland

4.2.2 Advancements in medical research leading to improved treatment options for AxSpA patients

4.2.3 Growing geriatric population in Ireland, which is more susceptible to AxSpA

4.3 Market Restraints

4.3.1 Limited access to specialized healthcare services for AxSpA patients in some regions of Ireland

4.3.2 High cost associated with AxSpA treatments and medications

4.3.3 Lack of trained healthcare professionals with expertise in managing AxSpA in Ireland

6.1 Ireland Axial Spondyloarthritis (axSpA) Market, By Types

6.1.1 Overview and Analysis

6.1.2 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Types, 2021- 2031F

6.1.3 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Ankylosing spondylitis (AS), 2021- 2031F

6.1.4 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Non-radiographic axial spondyloarthritis (nr-axSpA), 2021- 2031F

6.2 Ireland Axial Spondyloarthritis (axSpA) Market, By Drug Class

6.2.1 Overview and Analysis

6.2.2 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Non-steroidal anti-inflammatory drugs (NSAID), 2021- 2031F

6.2.3 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Glucocorticoids, 2021- 2031F

6.2.4 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Anti-rheumatic drugs, 2021- 2031F

6.2.5 Ireland Axial Spondyloarthritis (axSpA) Market Revenues & Volume, By Others, 2021- 2031F

7.1 Ireland Axial Spondyloarthritis (axSpA) Market Export to Major Countries

7.2 Ireland Axial Spondyloarthritis (axSpA) Market Imports from Major Countries

8.1 Average time from symptom onset to diagnosis of AxSpA in Ireland

8.2 Number of healthcare facilities offering specialized AxSpA treatment in Ireland

8.3 Patient satisfaction rates with AxSpA management and care services in Ireland

9.1 Ireland Axial Spondyloarthritis (axSpA) Market Opportunity Assessment, By Types, 2021 & 2031F

9.2 Ireland Axial Spondyloarthritis (axSpA) Market Opportunity Assessment, By Drug Class, 2021 & 2031F

10.1 Ireland Axial Spondyloarthritis (axSpA) Market Revenue Share, By Companies, 2024

10.2 Ireland Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking, By Operating and Technical Parameters